Blue Ocean Technologies & FlexTrade Systems Announce Connectivity Partnership
22.2.2023 17:04:00 EET | Business Wire | Press release
FlexTrade Systems (@FlexTrade), a global leader in high-performance multi-asset sell-side technology and Blue Ocean Technologies (BOT), a unique capital markets fintech leader in global afterhours trading, announced today a connectivity partnership to broaden access to FlexTrade’s sell-side order management solutions for broker-dealer subscribers. As part of the partnership, FlexTrade is offering broker-dealer clients access to the Blue Ocean ATS trading platform for after–hours trading in US equities from 8:00 pm – 4:00 am EST, further driving development within the 24-hour global equities trading sector.
Brian Hyndman, President and CEO of Blue Ocean Technologies and Blue Ocean ATS, commented, “We are delighted to partner with a respected industry leader such as FlexTrade. Blue Ocean Technologies average daily volume has grown 230% in 2023 from 2022, validating the overall need for the offering providing additional choices for investors that want to manage their risk., validating the overall need for the offering providing additional choices for investors that want to manage their risk. The expansion is due in large part to connectivity partnerships with trading platforms like FlexTrade Systems. With this newest partnership, FlexTrade is providing users with access to our Blue Ocean Sessions service, underscoring the importance of providing users with new routing choices, more trading flexibility, and transparency after hours. We are excited to continue growing our reach for traders globally,” he added.
FlexTrade Systems’ Shane Remolina, Director of Business Development, Sell-Side Trading Solutions added, “FlexTrade’s objectives include providing best-in-class service and support coupled with cutting-edge feature sets and functionality to our clients. Partnering with Blue Ocean is a natural fit and next step that will enable clients with large trading flows in the APAC region to access Blue Ocean’s overnight session in US names. We are extremely excited to have added Blue Ocean connectivity to FlexTrade’s already best-in-class institutional grade retail trading suite.”
About Blue Ocean Technologies:
Blue Ocean Technologies, LLC (BOT) is a unique capital markets fintech company empowering global investors by making trading possible during US overnight trading hours. Blue Ocean Technologies’ US broker dealer subsidiary, Blue Ocean ATS, LLC, and its trading system Blue Ocean Alternative Trading System (BOATS), currently trade US National Market System (NMS) stocks from 8:00 pm to 4:00 am ET from Sunday – Thursday. Founded in 2019, Blue Ocean ATS is on a mission to transform US trading to Global trading via its flagship service, Blue Ocean Session, providing access and transparency to subscribers in all time zones during non-traditional US market hours. Learn more about how to connect to: sales@blueoceanats. For additional information, please visit our website: www.blueocean-tech.io and follow us on LinkedIn and Twitter.
About FlexTrade Systems Sell-Side Trading Solutions:
FlexTrade Systems is a global financial technology firm that aims to boost trading efficiency by simplifying the complexities of today’s trading workflows through the provision of a unified multi-asset sell-side trading platform. Recognizing its mission-critical role, FlexTrade achieves this goal with unparalleled service and support for high touch and low touch businesses across cash, program trading, futures & options, ETF, swaps, and foreign exchange workflows. Whether the focus is on a market-making, agency, retail, or, proprietary trading desk, FlexTrade can enhance a broker-dealers complete order management lifecycle from order receipt, and trading, to middle and back-office workflows, in a single, technology platform.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005376/en/
Contact information
Blue Ocean Technologies
press@blueocean-tech.io
FlexTrade Systems
Matthew Halicki
Vice President, Marketing
matthew.halicki@flextrade.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 08:30:00 EET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe ® Launches LeukoStrat ® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 07:30:00 EET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 02:00:00 EET | Press release
VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise Reduction (CNR) and radial Lens Shading Correction (LSC), and featu
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 23:30:00 EET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom